Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
Europe Research & Development Regulation

‘Open & Constructive’: Early Feedback Supports Simultaneous Scientific Advice In Europe

16 Meetings Have Taken Place So Far

  • News

Executive Summary

A European pilot project that lets drug companies developing innovative products receive scientific advice from two EU member states at the same time is proving its worth during the pandemic.

You may also be interested in...



Migraine & Hepatitis B Prevention Products Among New EU Filings

The latest list of marketing authorization applications under review by the European Medicines Agency includes filings for eight new products.

Another EU Filing Targets Burgeoning NMOSD Market

Viela and Roche both now have marketing applications that are being reviewed by the European Medicines Agency. If approved in the EU, their products will compete with Alexion’s blockbuster Soliris.

Big Changes Kicking In Under Australia’s Personalized Medical Devices Rules

Most of the products currently supplied under Australia’s custom-made medical device exemption will no longer be eligible for supply in this way.

Table

View full table

Topics

Tags:
Europe Research & Development Regulation
UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By